Moreover, mutations altering pathways involved in prostate carcinogenesis including FOXA1‐, SPOP‐ and ATM‐regulated signals could be useful to discover new therapeutic targets for the treatment of metastatic PCa. The gene discussed is SPOP; the disease is posterior cortical atrophy.